Fact checked by Nick Blackmer The Centers for Disease Control and Prevention (CDC) has expanded the RSV vaccine ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

Ziresovir earns global recognition, boosting hope for young RSV patients and strengthening ArkBio’s innovative pipeline.

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing ...